For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...

Several Ohio medical spas including two in the Mahoning Valley were sent letters by the Ohio Attorney General's Office ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years ...

By December 2023, 12.3% of all glucose-lowering medication dispensations were tirzepatide among adults with T2DM.

Tirzepatide and GLP-1 receptor agonists are replacing older treatments, marking a shift in how diabetes and weight loss are ...

Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with ...

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

Researchers found that by December 2023, more than 1 in 3 of the medications being started for type 2 diabetes treatment were GLP-1RA-based medications.

Ohio Attorney General Dave Yost issued a warning to several Ohio medical spas over their alleged claims regarding weight-loss drugs.

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

The study finds better A1c lowering and weight reduction, but an expert clinician says practical issues may pose barriers.

When it comes to managing weight loss and type 2 diabetes with medications, research shows that it's out with the old and in ...